A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2017 - ard.bmj.com
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …
被引用次数：95 相关文章

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka, FF Cons-Molina… - repository.ajou.ac.kr
OBJECTIVE: To demonstrate pharmacokinetic equivalence of CT-P10 and innovator
rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or …

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka… - ANNALS OF THE …, 2017 - repository.hanyang.ac.kr
Objective To demonstrate pharmacokinetic equivalenceof CT-P10 and innovator rituximab
(RTX) in patientswith rheumatoid arthritis (RA) with inadequate responsesor intolerances to …

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2016 - europepmc.org
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …

[引用][C] A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid …

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2017 - elibrary.ru
[HTML] bmj.com

[HTML][HTML] A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid …

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2017 - ard.bmj.com
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka… - ANNALS OF THE …, 2017 - scholarworks.bwise.kr
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2017 - snucm.elsevierpure.com
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

DH Yoo, CH Suh, SC Shim, S Jeka… - Annals of the …, 2017 - search.proquest.com
Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab
(RTX) in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …